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donor CD41 and CD81 T cells and TNFa levels. Further studies
using strain combinations wherein donor and host mice differed at
either MHC class I (CD81 mediated IPS) or MHC class II
(CD41mediated IPS), and additional donor mice lacking TNFa re-
vealed that CD41 cells use both FasL and TNFa whereas CD81T
cells appear to use TNFa exclusively during the evolution of IPS.
We conclude that CTL activity is present in the lungs of mice
with IPS and that differential pathways for cell-mediated cytolysis
are used by CD41 andCD81T cells in this setting. These data con-
firm a role for cellular effector mechanisms in IPS and may provide
insight toward developing novel strategies for treating this serious
complication of allo-BMT.
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PHASE I-II STUDY OF CLOFARABINE-MELPHALAN-ALEMTUZUMAB CON-
DITIONING FOR ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTA-
TION (HCT) IN PATIENTS WITH ADVANCED HEMATOLOGIC
MALIGNANCIES: UNEXPECTED RENAL TOXICITY
van Besien, K., Kline, J., Godley, L., Larson, R.A., Odenike, O.,
Rich, E.S., Stock, W., Wickrema, A., Swanson, K., Horowitz, S., Del
Cerro, P., Schroeder, L., Pape, L., Allen, S., Artz, A.S. University of Chi-
cago, Chicago, IL
Fludarabine Melphalan-alemtuzumab (Flu-Mel-Camp) condi-
tioning has high recurrence rates . Clofarabine (Clo), a second gen-
eration nucleoside analog, might enhance disease control.We report
an ongoing phase I-II study of Clo-Mel-Camp conditioning.GVHD
prophylaxis used tacrolimus. For the phase I, one pt was enrolled per
level, until the first DLT or until 2 had gr 3 toxicity. Level 1 was: Clo
10 mg/m2/day on d -7 to -3 and Mel 100 mg/m2 on day -2. Clo was
increased by 10 mg per cohort until 40 mg/m2/d. Then Mel by 20
mg until 140 mg/m2. 12 pts were accrued in the phase I. 4 died
from TRM: 2 of early sepsis unrelated to Clo toxicity; 1 from
multi-organ failure and possible regimen related toxicity (RRT);
and 1at d159 from sepsis. The phase II dose was Clo 40 mg/m2/
day x 5 d and Mel 140 mg/m2. 3 pts in the phase I and 21 pts in
the phase II portion received this dose. Median age 53 (20–70); 17
Myeloid, 1 CLL, 15 NHL; 26 high or intermediate risk. 5 relapse
after alloHCT, 7 after auto HCT. HCT-CI was . 5 3 in 12 and
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MINIMAL MORTALITY FROM VENO-OCCLUSIVE DISEASE FOLLOWING
BUSULFAN-BASED PREPARATIVE REGIMENS: A LARGE SINGLE INSTITU-
TION EXPERIENCE
Sproat, L., Bolwell, B., Rybicki, L., Kalaycio, M., Dean, R., Sobecks, R.,
Pohlman, B., Andresen, S., Sweetenham, J., Copelan, E. Cleveland Clinic
Taussig Cancer Institute, Cleveland, OH
Hepatic veno-occlusive disease (VOD) is a frequently cited life
threatening limitation of busulfan containing regimens. Reported
incidence ranges from 5% to .50% and mortality rates can be
substantial. Using a prospectively maintained database, a retrospec-
tive analysis was conducted to identify patients undergoing autolo-
gous or myeloablative allogeneic stem cell transplant with
busulfan/cyclophosphamide or busulfan/cyclophosphamide/etopo-
side as the preparative regimen at a single institution from 1993–
2007. The objective was to estimate the mortality from VOD.
1508 transplant patients (1037 autologous and 471 allogeneic)
were identifiedwith 1 to 15 years of follow up. The autologous group
had VOD as the primary cause of death in only 3 patients (0.7% of
deaths, 0.3% total population). In this group the most common
cause of death was relapse (32% of total population, 74.9% of total
deaths). The cumulative incidence of non relapse mortality (NRM)
was 10.6% with respiratory failure (6.8%) being most common.
The allogeneic group had VOD as the primary cause of death in
only 8 patients (1.7% of total population, 2.4% of total deaths). In
this group themost common cause of death was relapse (22% of total
population, 31.1% of deaths). The cumulative incidence of NRM
was 47.8% with graft versus host disease (30.6%) being most com-
mon. Liver related mortality was not a significant factor in either
subset of patients. This is the largest single institution analysis on
the mortality risk of VOD following busulfan-based preparation.
Unlike some smaller previous reports, lethal VOD was infrequent
following busulfan-based preparation and not a significant cause of
mortality. When both autologous and allogeneic transplant groups
were combined, VOD was the primary cause of death in\1% of
patients. In conclusion, in a large single institution with significant
experience administering busulfan-based preparative regimens
for stem cell transplant VOD as a primary cause of death is extremely
low.289
DIFFERENTIAL MECHANISMS FOR CD41 AND CD81MEDIATED INFLAM-
MATION IN THE DEVELOPMENT OF EXPERIMENTAL IDIOPATHIC PNEU-
MONIA SYNDROME
Pierce, E.M.1, Hildebrandt, G.C.2, Askew, D.1, Eid, S.1, Jennings, A.1,
Cooke, K.R.1 1Case Western Reserve University, Cleveland, OH; 2Uni-
versity of Regensburg, Regensburg, Germany
Idiopathic pneumonia syndrome (IPS) is a frequently fatal compli-
cation following allogeneic BMT (allo-BMT). The pathophysiology
of IPS involves both soluble and cellular effectors. We examined the
role of cytolytic T lymphocyte (CTL) effector function in the devel-
opment of IPS using well-establishedmurine BMTmodels. In initial
experiments, lethally irradiated B6D2F1 (F1) recipient mice re-
ceived BMT from either allogeneic (B6) or syngeneic (F1) donors.
Mice were then analyzed for the development of IPS and for donor
T cell chimerism, cytokine phenotype, and CTL activity in the lungs
at specified points after BMT. At week six, allo-BMT recipients de-
veloped significant lung injury compared to syngeneic controls. Do-
nor T cell chimerism in the lungs was complete by week 2 after
BMT, and RT-PCR analysis in combination with intra-cytoplasmic
staining and flow cytometry demonstrated that donor CD41 and
CD81 cells had a Th1/Tc1 phenotype; T cells expressed IFNg,
TNFa and RANTES but not IL-4 or IL-5. Furthermore, mRNA
expression revealed that lungs from allo-BMT recipients expressed
high levels of perforin, FasL and Fas within the first 2 weeks com-
pared to syngeneic controls. Immunohistochemistry and FACS
analysis confirmed that protein levels of Fas were also increased in
the lung after allo-BMT. Significant CTL activity (chromium re-
lease assay) mediated by both perforin and FasL was present as early
as week 2 after BMT. Next, F1 animals received allo-BMT from ei-
ther wild type (WT) B6 donors or from B6 mice deficient in either
perforin (pfp -/-) or FasL (gld). Recipients of gld, but not pfp -/-
BMT developed less IPS compared to allo-controls as characterized
by reductions in pathology, BAL fluid cellularity, numbers of both
ECOG PS . 5 1 in 13. 18 had sib and 15 MUD donors. All evalu-
able pts engrafted. Median d 30 donor chimerism was 95% (14–100)
with no late graft failures. There were 3 deaths from TRM in the
phase II: 2 from RRT and 1 from GVHD. Grade 3–4 renal toxicity
occurred between day -7 and day 17 in 4 of 24 (17%) pts receiving
full dose Clo and Mel. Only1 has recovered. No grade 3 renal
toxicity occurred between day -7 and day 17 among 112 pts on
Flu-Mel-Camp(p \ 0.000). In addition grade 2 renal failure
occurred in 8 pts, reversible in 5. Other toxicities included: gr 2–3
reversible ALT elevation in 17 pts; gr 2 reversible bilirubin elevation
in 2 pts; gr 2–3 hand-foot syndrome in 10 pts; gr 3 mucositis and pul-
monary hemorrhage in 1 pt;Withmedian follow-up of 175 days (12–
487), 3 of 12 in the phase I, and 16 of 21 pts in the phase II portion
remain in remission. Estimated day 180 progression-free survival is
53% (95% CI: 34–72) with no failures beyond day 160.
Conclusions: Clo-Mel-Camp induces durable engraftment.
Response and duration of response are encouraging. Common tox-
icities are elevation of transaminases, hand foot syndrome and grade
2–4 renal failure. There were seven TRM, all in pts with high risk
disease, prior transplant and/or multiple comorbidities. Three
TRM were attributed to Clo toxicity and occurred in the context
of early onset grade 3–4 renal failure. Because of this, the Clo dose
will be reduced to 30 mg/m2/day x 5 days.
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TOTAL MARROW AND LYMPH NODE IRRADIATION (TMLI) WITH
FLUDARABINE (FLU) AND MELPHALAN (MEL) IS WELL TOLERATED
AND MAY RESULT IN IMPROVED OUTCOME IN PATIENTS (PTS) WITH
ADVANCED HEMATOLOGICAL MALIGNANCIES
Rosenthal, J.1, Wong, J.2, Stein, A.1, Naeem, H.3, Hitt, D.1, Forman, S.1
1City of Hope, Duarte, CA; 2City of Hope; 3City of Hope
Reduced intensity conditioning (RIC) with FLU/MEL followed
by hematopoietic stem cell transplantation (HSCT) may result in
